At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
E7080drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
In Brief
A Phase 1 clinical trial evaluating E7080 for Cancer: Solid Tumors. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the maximum tolerable dose (MTD) and the related effects of E7080 administered to patients with solid tumors that are resistant to approved existing anti-tumor therapies, or for which no appropriate treatment is available.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer: Solid Tumors
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedJan 2006
Primary CompletionSep 2008
Study CompletionNov 2008
TodayJul 2026
First PostedJan 23, 2006
Enrollment StartJan 1, 2006
Primary CompletionSep 1, 2008
Study CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 20.4 years ago
Interventions
E7080drug
E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.